Globally launched clinical trials like the European study DISCOVERY showed that antiviral drugs (remdesivir, lopinavir and ritonavir in combination, ritonavir given with or without interferon beta and hydroxychloroquine) are unable to efficiently attack COVID-19 progression (Ader et al., 2022)
This BPC-157 + TB-500 research peptide blend is manufactured to exceed 99% purity and tested using both HPLC and LC-MS protocols to support analytical confidence, identity confirmation, and batch-to-batch consistency
Here are the most common recommendations: The sweet spot for most peptides and most protocols is a concentration that allows you to draw between 5 and 30 units per dose
Secondary site: The medial epicondyle area (the bony bump on the inner side just above the joint line)
& Er, S
Gironi M, Borgiani B, Farina E, Mariani E, Cursano C, Alberoni M, et al